This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chen, L. Articles by Waxm, D. J. Search for Related Content PubMed PubMed Citation Articles by Chen, L. Articles by Waxm, D. J.

Potentiation of Cytochrome P450/Cyclophosphamide-based Cancer Gene Therapy by Coexpression of the P450 Reductase Gene¹

Division of Cell and Molecular Biology, Department of Biology, Boston University, Boston, Massachusetts 02215

Intratumoral expression of cytochrome P450 2B1 sensitizes tumor cells to the cytotoxic action of the alkylating agent prodrug cyclophosphamide (CPA) and provides a novel strategy for cancer gene therapy that may enhance the selectivity and the effectiveness of this class of antitumor drugs [L. Chen and D. J. Waxman, Cancer Res., 55: 581–589, 1995]. P450-catalyzed drug metabolism is obligatorily dependent on electron input from the flavoenzyme NADPH-P450 reductase (RED), which is widely expressed in many cell types, including tumor cells. Here, we investigate the potential utility of combining RED gene transfer with CPA-based P450 gene therapy. Rat 9L gliosarcoma cells stably expressing either basal or elevated (up to 10-fold increase) levels of RED, in the presence or absence of P450 2B1, were selected and characterized. RED overexpression substantially increased the sensitivity of these cells to CPA, but only when combined with P450 2B1 expression. An enhanced cytotoxic response was also obtained when recombinant adenovirus encoding P450 2B1 was used to deliver the P450 gene to RED-overexpressing tumor cells. CPA cytotoxicity was substantially decreased by the RED inhibitor diphenyleneiodonium chloride or by the P450 inhibitor metyrapone, providing evidence of its dependence on the catalytic contributions of both protein components of the P450 metabolic pathway. Conditioned media from P450 2B1-expressing and RED-overexpressing tumor cells treated with CPA exhibited increased formation of the primary 4-hydroxy metabolite and greater cell contact-independent bystander cytotoxic potential compared to tumor cells containing P450 2B1 and basal levels of RED. Evaluation of the impact of P450/RED combination gene therapy using a s.c. solid tumor model/tumor excision assay revealed a dramatic 50-100-fold increase in tumor cell kill in vivo over that provided by liver drug activation alone. These findings establish the importance of endogenous RED levels as a determinant of the sensitivity of tumor cells to CPA/P450 gene therapy and demonstrate the striking therapeutic effectiveness of an anticancer prodrug activation strategy based on the combination of a cytochrome P450 gene with the gene encoding RED.

¹ This work was supported in part by NIH Grant CA49248 (to D. J. W.).

² Present address: Department of Human Genetics, Merck Research Laboratories, WP26A-3000, West Point, PA 19486.

³ Present address: Department of Drug Metabolism, Pfizer Central Research, Groton, CT 06340.

⁴ To whom requests for reprints should be addressed, at Department of Biology, Boston University, 5 Cummington Street, Boston, MA 02215. Phone: (617) 353-7401; Fax: (617) 353-7404; E-mail: djw@bio.bu.edu.

Received 6/11/97. Accepted 9/ 5/97.

This article has been cited by other articles:

				S.-L. Wang, J.-F. Han, X.-Y. He, X.-R. Wang, and J.-Y. Hong Genetic Variation of Human Cytochrome P450 Reductase as a Potential Biomarker for Mitomycin C-Induced Cytotoxicity Drug Metab. Dispos., January 1, 2007; 35(1): 176 - 179. [Abstract] [Full Text] [PDF]

				Y. Jounaidi, C.-S. Chen, G. J. Veal, and D. J. Waxman Enhanced antitumor activity of P450 prodrug-based gene therapy using the low Km cyclophosphamide 4-hydroxylase P450 2B11. Mol. Cancer Ther., March 1, 2006; 5(3): 541 - 555. [Abstract] [Full Text] [PDF]

				M. Michael and M.M. Doherty Tumoral Drug Metabolism: Overview and Its Implications for Cancer Therapy J. Clin. Oncol., January 1, 2005; 23(1): 205 - 229. [Abstract] [Full Text] [PDF]

				Y. Jounaidi and D. J. Waxman Use of Replication-Conditional Adenovirus as a Helper System to Enhance Delivery of P450 Prodrug-Activation Genes for Cancer Therapy Cancer Res., January 1, 2004; 64(1): 292 - 303. [Abstract] [Full Text] [PDF]

				D. Saha, K. R. Sekhar, C. Cao, J. D. Morrow, H. Choy, and M. L. Freeman The Antiangiogenic Agent SU5416 Down-Regulates Phorbol Ester-Mediated Induction of Cyclooxygenase 2 Expression by Inhibiting Nicotinamide Adenine Dinucleotide Phosphate Oxidase Activity Cancer Res., October 15, 2003; 63(20): 6920 - 6927. [Abstract] [Full Text] [PDF]

				C. J. A. Ring Cytolytic viruses as potential anti-cancer agents J. Gen. Virol., March 1, 2002; 83(3): 491 - 502. [Abstract] [Full Text] [PDF]

				G. Xu and H. L. McLeod Strategies for Enzyme/Prodrug Cancer Therapy Clin. Cancer Res., November 1, 2001; 7(11): 3314 - 3324. [Abstract] [Full Text] [PDF]

				P. Y.P. Lam and X. O. Breakefield Potential of gene therapy for brain tumors Hum. Mol. Genet., April 1, 2001; 10(7): 777 - 787. [Abstract] [Full Text] [PDF]

				Y. Jounaidi and D. J. Waxman Combination of the Bioreductive Drug Tirapazamine with the Chemotherapeutic Prodrug Cyclophosphamide for P450/P450-Reductase-based Cancer Gene Therapy Cancer Res., July 1, 2000; 60(14): 3761 - 3769. [Abstract] [Full Text]

				M. Aghi, T. C. Chou, K. Suling, X. O. Breakefield, and E. A. Chiocca Multimodal Cancer Treatment Mediated by a Replicating Oncolytic Virus That Delivers the Oxazaphosphorine/Rat Cytochrome P450 2B1 and Ganciclovir/Herpes Simplex Virus Thymidine Kinase Gene Therapies Cancer Res., August 1, 1999; 59(16): 3861 - 3865. [Abstract] [Full Text] [PDF]

				L. J. Yu, P. Drewes, K. Gustafsson, E. G. C. Brain, J. E. D. Hecht, and D. J. Waxman In Vivo Modulation of Alternative Pathways of P-450-Catalyzed Cyclophosphamide Metabolism: Impact on Pharmacokinetics and Antitumor Activity J. Pharmacol. Exp. Ther., March 1, 1999; 288(3): 928 - 937. [Abstract] [Full Text]